Atb Cap Markets Brokers Boost Earnings Estimates for Tilray

Tilray Inc (NASDAQ:TLRY) – Analysts at Atb Cap Markets increased their FY2025 EPS estimates for shares of Tilray in a report issued on Monday, December 16th. Atb Cap Markets analyst F. Gomes now anticipates that the company will post earnings of ($0.13) per share for the year, up from their previous estimate of ($0.14). The consensus estimate for Tilray’s current full-year earnings is ($0.14) per share. Atb Cap Markets also issued estimates for Tilray’s FY2026 earnings at ($0.11) EPS, FY2027 earnings at ($0.04) EPS and FY2029 earnings at $0.05 EPS.

Separately, Roth Mkm reduced their target price on Tilray from $2.00 to $1.75 and set a “neutral” rating on the stock in a report on Friday, October 11th.

Tilray Stock Performance

Shares of TLRY traded up $0.05 during midday trading on Thursday, reaching $1.21. 5,708,618 shares of the stock were exchanged, compared to its average volume of 25,748,680. Tilray has a twelve month low of $1.15 and a twelve month high of $2.97. The company has a quick ratio of 1.57, a current ratio of 2.47 and a debt-to-equity ratio of 0.08. The stock’s 50 day simple moving average is $1.45 and its 200 day simple moving average is $1.66. The company has a market cap of $1.09 billion, a P/E ratio of -4.48 and a beta of 2.08.

Tilray (NASDAQ:TLRY) last posted its quarterly earnings results on Thursday, October 10th. The company reported ($0.04) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.04). The business had revenue of $200.00 million for the quarter, compared to analysts’ expectations of $218.70 million. Tilray had a negative return on equity of 2.00% and a negative net margin of 26.79%. The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.10) EPS.

Insiders Place Their Bets

In other news, CFO Carl A. Merton purchased 26,000 shares of the company’s stock in a transaction dated Friday, November 15th. The shares were purchased at an average price of $1.36 per share, for a total transaction of $35,360.00. Following the transaction, the chief financial officer now owns 26,000 shares of the company’s stock, valued at approximately $35,360. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.87% of the company’s stock.

Institutional Trading of Tilray

Several hedge funds have recently modified their holdings of TLRY. Ferguson Wellman Capital Management Inc. acquired a new stake in Tilray in the 3rd quarter valued at $26,000. Signature Estate & Investment Advisors LLC bought a new position in Tilray during the 2nd quarter valued at $29,000. Jeppson Wealth Management LLC bought a new stake in shares of Tilray in the 2nd quarter worth $33,000. Vanguard Capital Wealth Advisors bought a new position in shares of Tilray during the second quarter valued at about $34,000. Finally, Pallas Capital Advisors LLC bought a new stake in Tilray in the 2nd quarter worth about $37,000. Institutional investors own 9.35% of the company’s stock.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.